Related Experiment Video
Updated: Dec 17, 2025

Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
Emerging role of microRNAs in ischemic stroke with comorbidities
Yu Qian1, Michael Chopp2, Jieli Chen1
1Department of Neurology, Henry Ford Hospital, Detroit, MI, United States of America.
Abstract:
Ischemic stroke is one of the major causes of global disability and death. Comorbidities in stroke are not only risk factors for an increased incidence of stroke, but also adversely impact stroke outcome. Stroke patients with co-morbidities have worse deficit, long term disability and high mortality rate and extended hospitalization stay. MicroRNAs (miRNAs) are noncoding RNA molecules, and are emerging as key molecular mediators of ischemic stroke and other diseases. Thus, focusing on the treatment of stroke and its comorbidities with miRNAs appears to be particularly important. In this review article, we provide an overview of the common comorbidities of hypertension, diabetes mellitus (DM) and hyperlipidemia in ischemic stroke. We also discuss specific miRNAs, including miR-126, miR-223, and miR-124 which are important in regulating ischemic stroke and describetheir effects as related to stroke and comorbidities. In addition, we provide an overview of roles of long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in stroke with comorbidities.
Insights
This review explores how microRNAs (miRNAs) impact ischemic stroke and common comorbidities like hypertension and diabetes. Understanding these molecular mediators is crucial for developing new stroke treatments.
Area of Science:
- Biomedical Science
- Molecular Biology
- Neurology
Background:
- Ischemic stroke is a leading cause of death and disability worldwide.
- Comorbidities significantly worsen stroke outcomes, increasing deficits, mortality, and hospitalization.
- MicroRNAs (miRNAs) are key molecular regulators implicated in ischemic stroke and associated conditions.
Purpose of the Study:
- To review common comorbidities in ischemic stroke: hypertension, diabetes mellitus (DM), and hyperlipidemia.
- To discuss the role of specific miRNAs (miR-126, miR-223, miR-124) in ischemic stroke and comorbidities.
- To provide an overview of long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in stroke with comorbidities.
Main Methods:
- Literature review of scientific articles on ischemic stroke, comorbidities, and non-coding RNAs.
- Analysis of the regulatory functions of specific miRNAs in stroke pathogenesis.
- Synthesis of current knowledge on lncRNAs and circRNAs in the context of stroke and comorbidities.
Main Results:
- Hypertension, DM, and hyperlipidemia are prevalent comorbidities that negatively affect stroke prognosis.
- Specific miRNAs, including miR-126, miR-223, and miR-124, play critical roles in modulating ischemic stroke and its associated comorbidities.
- lncRNAs and circRNAs also emerge as significant players in the pathophysiology of stroke with comorbidities.
Conclusions:
- Targeting miRNAs offers a promising therapeutic avenue for treating ischemic stroke and its comorbidities.
- Further research into the roles of lncRNAs and circRNAs may reveal novel therapeutic strategies for stroke management.
- A comprehensive understanding of molecular mediators is essential for improving patient outcomes in ischemic stroke with comorbidities.
More Related Videos
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
MicroRNAs
MicroRNAs
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...

